Pfizer (NYSE:PFE – Get Free Report) had its price objective raised by stock analysts at Guggenheim from $35.00 to $36.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price would indicate a potential upside of 34.47% from the stock’s current price.
Several other research analysts also recently issued reports on the company. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research note on Thursday, February 12th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. TD Cowen restated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. Finally, Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the company a “positive” rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $28.19.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.63 earnings per share. As a group, equities analysts anticipate that Pfizer will post 2.95 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in PFE. Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. State Street Corp raised its position in shares of Pfizer by 0.5% in the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after buying an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares during the period. Norges Bank purchased a new position in shares of Pfizer during the second quarter valued at approximately $2,270,157,000. Finally, Morgan Stanley boosted its position in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after acquiring an additional 14,342,946 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Phase 3 VALOR topline showed strong efficacy (reported ~73% in pre-specified analysis), giving the program clear commercial potential if approved. Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
- Positive Sentiment: Pfizer says it will seek regulatory review despite the trial miss, keeping a commercialization path alive and signaling management confidence in the data package. Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
- Positive Sentiment: Momentum and defensive income appeal: analysts and outlets note PFE’s stronger YTD performance and attractive dividend yield, factors that support investor interest amid broader market weakness. 5 High-Yield Stocks to Shield Your Portfolio From the Storm (PFE)
- Neutral Sentiment: The trial failed to meet its predefined primary endpoint because Lyme incidence was lower than expected; companies emphasize clinically meaningful efficacy on other statistical measures — outcome is data-positive but not conclusive. An experimental Lyme disease vaccine … findings aren’t conclusive (WSJ)
- Neutral Sentiment: Partner market reaction was severe (Valneva shares plunged), reflecting investor concern about statistical robustness and potential regulatory hurdles — a signal of market skepticism but not necessarily a direct hit to Pfizer’s balance sheet. Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
- Negative Sentiment: Missing the primary endpoint complicates the regulatory and commercial outlook — regulators could request additional analyses, labeling constraints, or more data, which would delay or reduce near-term revenue potential from the vaccine. Pfizer’s Lyme Vaccine Misses Mark in Study, Complicating Quest for Approval
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Recommended Stories
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
